Wells Fargo & Company Lowers Inspire Medical Systems (NYSE:INSP) Price Target to $56.00

Inspire Medical Systems (NYSE:INSP) had its price objective lowered by Wells Fargo & Company from $70.00 to $56.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price target would suggest a potential upside of 22.22% from the stock’s current price.

Several other research firms have also recently issued reports on INSP. Mizuho decreased their price objective on Inspire Medical Systems from $70.00 to $55.00 and set an “outperform” rating on the stock in a report on Tuesday. Oppenheimer cut Inspire Medical Systems from an “outperform” rating to a “market perform” rating in a report on Thursday, January 22nd. Evercore reaffirmed an “outperform” rating on shares of Inspire Medical Systems in a research report on Friday, February 27th. Zacks Research lowered Inspire Medical Systems from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, April 14th. Finally, Wolfe Research lowered Inspire Medical Systems from an “outperform” rating to a “peer perform” rating in a research report on Friday, February 13th. Four equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Inspire Medical Systems has an average rating of “Hold” and a consensus price target of $94.11.

Inspire Medical Systems Stock Down 16.4%

Shares of INSP stock traded down $9.02 during mid-day trading on Tuesday, hitting $45.82. 1,025,019 shares of the company’s stock were exchanged, compared to its average volume of 1,174,185. Inspire Medical Systems has a fifty-two week low of $44.41 and a fifty-two week high of $163.35. The stock has a 50-day simple moving average of $56.73 and a two-hundred day simple moving average of $79.64. The stock has a market cap of $1.32 billion, a price-to-earnings ratio of 9.15, a PEG ratio of 2.92 and a beta of 0.83.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings data on Monday, May 4th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.38. Inspire Medical Systems had a return on equity of 10.96% and a net margin of 15.95%.The business had revenue of $204.58 million for the quarter, compared to analysts’ expectations of $200.04 million. During the same quarter last year, the firm earned $0.10 earnings per share. The business’s revenue was up 1.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. As a group, analysts anticipate that Inspire Medical Systems will post 1.82 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Principal Financial Group Inc. raised its position in shares of Inspire Medical Systems by 1.0% in the 1st quarter. Principal Financial Group Inc. now owns 126,788 shares of the company’s stock worth $6,540,000 after buying an additional 1,269 shares during the period. Fifth Third Bancorp raised its position in shares of Inspire Medical Systems by 1,794.4% in the 1st quarter. Fifth Third Bancorp now owns 6,441 shares of the company’s stock worth $332,000 after buying an additional 6,101 shares during the period. New York State Teachers Retirement System raised its position in Inspire Medical Systems by 9.3% in the first quarter. New York State Teachers Retirement System now owns 23,599 shares of the company’s stock valued at $1,217,000 after purchasing an additional 2,004 shares during the period. Y Intercept Hong Kong Ltd raised its position in Inspire Medical Systems by 124.1% in the first quarter. Y Intercept Hong Kong Ltd now owns 158,274 shares of the company’s stock valued at $8,164,000 after purchasing an additional 87,639 shares during the period. Finally, Leonteq Securities AG raised its position in Inspire Medical Systems by 187.3% in the first quarter. Leonteq Securities AG now owns 22,812 shares of the company’s stock valued at $1,177,000 after purchasing an additional 14,873 shares during the period. 94.91% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Inspire Medical Systems

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q1 results beat estimates — Inspire reported $0.10 EPS (vs. consensus loss) and $204.6M revenue, topping Street expectations and showing modest year-over-year sales growth. This supports the company’s underlying business strength. GlobeNewswire: Q1 Results
• Neutral Sentiment: Analyst note: Mizuho cut its price target from $70 to $55 but kept an “outperform” rating — the new target offers almost no upside versus the current price, so it is mixed (still favorable rating but lower conviction on upside). Benzinga
• Neutral Sentiment: Company materials and call transcript are available for investors reviewing management commentary and the details behind the guidance change. Earnings Call Summary (Yahoo)
• Negative Sentiment: Guidance cut — Inspire narrowed FY2026 EPS guidance to $0.75–$1.25 (street ~$1.99) and revenue to $825M–$875M (street ~$961M). Management cited reimbursement/coding issues and WISeR disruption as drivers of the downgrade, which materially reduces expected growth and margins. Seeking Alpha: Guidance & WISeR Disruption
• Negative Sentiment: Analyst downgrades/price-target cuts — Robert W. Baird cut its target to $50 and moved to “neutral”; Bank of America reaffirmed “neutral” with a $53 target. Those moves signal reduced analyst confidence and put further pressure on the shares. The Fly: Baird Note
• Negative Sentiment: Market reaction: coverage and headlines emphasizing the guidance cut and reimbursement uncertainty drove a sharp intraday sell-off (coverage noted a large single-day decline following the update). Yahoo Finance: Stock Reaction

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.